2/23
04:37 pm
mgrx
Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study [Yahoo! Finance]
Low
Report
Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study [Yahoo! Finance]
2/23
04:05 pm
mgrx
Mangoceuticals’ Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study
Medium
Report
Mangoceuticals’ Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study
2/19
04:05 pm
mgrx
MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program
High
Report
MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program
12/19
02:17 pm
mgrx
Top Midday Decliners [Yahoo! Finance]
Medium
Report
Top Midday Decliners [Yahoo! Finance]
12/19
10:38 am
mgrx
Mangoceuticals, Inc. Announces Closing of $2.5 Million Registered Direct and Private Placements
High
Report
Mangoceuticals, Inc. Announces Closing of $2.5 Million Registered Direct and Private Placements
12/19
07:30 am
mgrx
Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy
High
Report
Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy
12/18
08:30 am
mgrx
Mangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq Rules
High
Report
Mangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq Rules
12/9
04:25 pm
mgrx
Mangoceuticals (NASDAQ:MGRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Mangoceuticals (NASDAQ:MGRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.